A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
Attention Deficit Hyperactivity Disorder
About this trial
This is an interventional treatment trial for Attention Deficit Hyperactivity Disorder
Eligibility Criteria
Inclusion Criteria:
Subjects with a diagnosis of Attention Deficit Hyperactivity Disorder, based on clinical assessment and interview.
Male and female outpatients. Subjects with a diagnosis of Attention Deficit Hyperactivity Disorder, based on clinical assessment and interview.
Female subjects must be of non-childbearing potential.
Exclusion Criteria:
Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including hypertension), hepatic, neurologic, or allergic disease.
Current or lifetime history of psychosis or bipolar disorder; any current anxiety disorder (with the exception of social or specific phobia), or substance abuse or dependence in the past 6 months.
Current episode of Major Depression or episode within the last 6 months.
Sites / Locations
- Bay Area Research Institute
- Pharmacology Research Institute
- Pharmacology Research Institute
- The University of Illinois at Chicago, Institute for Juvenile Research
- Massachusetts General Hospital, ADHD Program
- New York University School of Medicine
- NeuroScience, Inc
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Placebo Comparator
Experimental
Flexible Dose
Placebo
Fixed Dose